DCPH Deciphera Pharmaceuticals, Inc. Stock Quote

DCPH [NASD]

Index	-	P/E	-	EPS (ttm)	-4.79	Insider Own	0.20%	Shs Outstand	57.23M	Perf Week	0.87%
Market Cap	2.41B	Forward P/E	-	EPS next Y	-2.65	Insider Trans	-69.95%	Shs Float	41.00M	Perf Month	-12.82%
Income	-266.50M	PEG	-	EPS next Q	-1.09	Inst Own	75.40%	Short Float	6.61%	Perf Quarter	-28.45%
Sales	42.10M	P/S	57.21	EPS this Y	-6.50%	Inst Trans	0.97%	Short Ratio	6.14	Perf Half Y	-5.29%
Book/sh	9.50	P/B	4.52	EPS next Y	37.20%	ROA	-39.20%	Target Price	75.00	Perf Year	-25.48%
Cash/sh	9.84	P/C	4.36	EPS next 5Y	21.00%	ROE	-44.30%	52W Range	33.10 - 68.40	Perf YTD	-24.72%
Dividend	-	P/FCF	-	EPS past 5Y	-49.20%	ROI	-49.90%	52W High	-37.19%	Beta	1.52
Dividend %	-	Quick Ratio	8.30	Sales past 5Y	-	Gross Margin	99.50%	52W Low	29.79%	ATR	2.50
Employees	350	Current Ratio	8.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	37.11	Volatility	5.63% 5.36%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	16.30%	Profit Margin	-	Rel Volume	1.73	Prev Close	44.31
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Feb 09 AMC	Payout	-	Avg Volume	441.65K	Price	42.96
Recom	1.70	SMA20	-7.67%	SMA50	-14.05%	SMA200	-19.89%	Volume	762,912	Change	-3.05%

Feb-10-21

Upgrade

SVB Leerink

Mkt Perform → Outperform

$70

Dec-03-20

Initiated

Stifel

Buy

$75

Sep-14-20

Resumed

JP Morgan

Neutral

$52

May-07-20

Downgrade

Nomura

Buy → Neutral

$84 → $60

Mar-04-20

Initiated

Barclays

Overweight

$70

Dec-20-19

Reiterated

Jefferies

Buy

$53 → $77

Oct-29-19

Upgrade

SVB Leerink

Underperform → Mkt Perform

$29 → $34

Oct-22-19

Initiated

JMP Securities

Mkt Outperform

Oct-03-19

Initiated

H.C. Wainwright

Buy

$60

Sep-30-19

Initiated

Jefferies

Buy

$47

Jul-18-19

Initiated

Deutsche Bank

Buy

$42

Dec-31-18

Upgrade

B. Riley FBR

Neutral → Buy

$27 → $34

Sep-25-18

Initiated

Leerink Partners

Underperform

Aug-29-18

Initiated

Raymond James

Outperform

$47

Jul-05-18

Initiated

SunTrust

Buy

Jun-19-18

Downgrade

B. Riley FBR, Inc.

Buy → Neutral

$43

Feb-16-18

Initiated

B. Riley FBR, Inc.

Buy

$43

Oct-23-17

Initiated

Piper Jaffray

Overweight

$35

Oct-23-17

Initiated

Nomura

Buy

Oct-23-17

Initiated

JP Morgan

Overweight

$30

Mar-02-21 07:00AM	Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference Business Wire
Feb-18-21 07:00AM	Deciphera Pharmaceuticals, Inc. to Present at the SVB Leerink 10th Annual Global Healthcare Conference Business Wire
Feb-10-21 11:29PM	Broker Revenue Forecasts For Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Are Surging Higher Simply Wall St.
10:21AM	Deciphera (DCPH) Reports Narrower-Than-Expected Q4 Loss Zacks
10:05AM	Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2021 Benzinga
Feb-09-21 10:00PM	Deciphera Pharmaceuticals, Inc. (DCPH) Q4 2020 Earnings Call Transcript Motley Fool
05:31PM	Recap: Deciphera Pharmaceuticals Q4 Earnings Benzinga
05:15PM	Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:01PM	Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results Business Wire
02:30PM	Deciphera Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-08-21 09:58AM	Baudax (BXRX) to Report Q4 Earnings: What's in the Cards? Zacks
12:35AM	Investors Who Bought Deciphera Pharmaceuticals (NASDAQ:DCPH) Shares Three Years Ago Are Now Up 97% Simply Wall St.
Feb-04-21 07:00AM	Deciphera Pharmaceuticals, Inc. to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day Business Wire +8.96%
Feb-02-21 07:00AM	Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call and Webcast on February 9, 2021 Business Wire +7.46%
Jan-11-21 07:00AM	Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Corporate Milestones Business Wire
Jan-05-21 07:23AM	Deciphera Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference Business Wire -5.16%
Dec-20-20 10:04PM	DCPH Stock Forecast: Where Do Hedge Funds Stand? Insider Monkey
Dec-18-20 12:14PM	The Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, uniQure, REGENXBIO and Deciphera Pharmaceuticals Zacks
Dec-01-20 10:04AM	Deciphera (DCPH) Ends Qinlock Second-Line GIST Study Enrollment Zacks
Nov-30-20 07:00AM	Deciphera Pharmaceuticals Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK® (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal Tumor Business Wire
Nov-24-20 04:01PM	Deciphera Pharmaceuticals, Inc. to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference Business Wire
Nov-23-20 07:00AM	The Boston Globe Names Deciphera a Top Place to Work for 2020 Business Wire
Nov-11-20 07:01AM	Deciphera Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting Business Wire
07:00AM	Deciphera Presents Updated Preliminary Data from DCC-3014, its CSF1R Inhibitor Program, in Tenosynovial Giant Cell Tumor Patients at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting Business Wire
Nov-10-20 07:00AM	Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference Business Wire
05:29AM	News Flash: Analysts Just Made A Sizeable Upgrade To Their Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Forecasts Simply Wall St.
Nov-09-20 10:18AM	Deciphera (DCPH) Reports Narrower-Than-Expected Loss in Q3 Zacks +7.43%
Nov-06-20 10:31PM	Deciphera Pharmaceuticals, Inc. (DCPH) Q3 2020 Earnings Call Transcript Motley Fool -7.01%
Nov-05-20 04:01PM	Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results Business Wire
02:45PM	Deciphera Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Oct-28-20 07:00AM	Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 5, 2020 Business Wire
Sep-22-20 04:23PM	Blueprint Medicines Reports Positive Test Results For Rare Disease Treatment; BPMC Stock Jumps Investor's Business Daily
Sep-20-20 09:12AM	An Intrinsic Calculation For Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Suggests It's 48% Undervalued Simply Wall St.
Sep-18-20 07:00AM	Deciphera Presents Data from QINLOCK (Ripretinib) Program in Patients with Gastrointestinal Stromal Tumor at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 Business Wire +6.66%
Sep-17-20 07:00AM	Deciphera Presents Data from Rebastinib, its TIE2 Inhibitor Program, at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 Business Wire
Sep-15-20 12:48AM	Hedge Funds Never Been This Bullish On Deciphera Pharmaceuticals, Inc. (DCPH) Insider Monkey
Aug-17-20 04:30PM	Deciphera Announces Publication of QINLOCK (ripretinib) Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical Oncology Business Wire
Aug-06-20 08:40AM	Deciphera Pharmaceuticals, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference Business Wire
Aug-05-20 08:01AM	Deciphera Pharmaceuticals, Inc. (DCPH) Q2 2020 Earnings Call Transcript Motley Fool
Aug-04-20 06:25PM	Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM	Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial Results Business Wire
Jul-29-20 07:00AM	Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 4, 2020 Business Wire
Jul-20-20 10:39AM	China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor PR Newswire
07:30AM	China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor GlobeNewswire
Jul-14-20 07:00AM	Deciphera Announces Australian Therapeutic Goods Administrations Approval of QINLOCK (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor Business Wire
Jul-12-20 08:15PM	Did Hedge Funds Make The Right Call On Deciphera Pharmaceuticals, Inc. (DCPH) ? Insider Monkey
Jul-09-20 08:01AM	Industry Analysts Just Upgraded Their Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Revenue Forecasts By 12% Simply Wall St.
Jul-02-20 04:01PM	Deciphera Announces Presentation of Analysis of Crossover Population from the INVICTUS Phase 3 Study of QINLOCK (ripretinib) in Patients with Fourth-Line Advanced GIST Business Wire
Jun-22-20 07:00AM	Deciphera Announces Health Canadas Authorization of QINLOCK (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor Business Wire
Jun-17-20 07:36PM	3 Strong Buy Healthcare Stocks That Should Remain Healthy TipRanks
Jun-11-20 07:00AM	Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Forum Business Wire -6.93%
Jun-08-20 07:30AM	Deciphera Announces Publication of the INVICTUS Pivotal Phase 3 Study of QINLOCK (ripretinib) in The Lancet Oncology Business Wire
02:56AM	Hedge Funds Have Never Been More Bullish On Deciphera Pharmaceuticals, Inc. (DCPH) Insider Monkey
Jun-03-20 07:11AM	The Debate Is Over: This Cancer Stock Is Winning the GIST Race Motley Fool
May-29-20 08:05AM	Deciphera Pharmaceuticals Presents Preliminary Data from Phase 1b/2 Study of Rebastinib in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer at the ASCO 2020 Virtual Scientific Program Business Wire
08:00AM	Deciphera Pharmaceuticals Announces Presentations of Positive Patient Reported Outcomes Results from INVICTUS Phase 3 Study of QINLOCKTM (ripretinib) in Patients with Fourth-Line Advanced GIST at the ASCO 2020 Virtual Scientific Program Business Wire
May-27-20 07:00AM	Deciphera Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference Business Wire
May-26-20 07:06AM	News Flash: Analysts Just Made A Captivating Upgrade To Their Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Forecasts Simply Wall St.
May-23-20 07:34AM	FDA Approval Could Be a Game-Changer for Deciphera Pharmaceuticals Motley Fool
May-18-20 04:16PM	Deciphera Pharmaceuticals Just Surged Higher On A Rapid Approval Investor's Business Daily +6.82%
12:22PM	Deciphera (DCPH) Secures Early FDA Nod for GIST Drug Qinlock Zacks
06:15AM	Nomura Sticks to Their Hold Rating for Deciphera Pharmaceuticals Investing.com
May-15-20 06:34PM	FDA Grants Full Approval of Deciphera Pharmaceuticals QINLOCK (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor Business Wire +6.75%
May-12-20 06:53AM	Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Analysts Just Trimmed Their Revenue Forecasts By 14% Simply Wall St. -6.77%
May-08-20 09:25AM	Earnings Update: Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Just Reported And Analysts Are Trimming Their Forecasts Simply Wall St.
May-06-20 12:01PM	Deciphera Pharmaceuticals, Inc. (DCPH) Q1 2020 Earnings Call Transcript Motley Fool
May-05-20 06:35PM	Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:01PM	Deciphera Pharmaceuticals, Inc. Announces First Quarter 2020 Financial Results Business Wire
May-04-20 01:36PM	Eaton Vance Worldwide Health Sciences Fund Adds 3 Stocks to Portfolio GuruFocus.com +7.43%
08:45AM	Is a Surprise Coming for Deciphera (DCPH) This Earnings Season? Zacks
Apr-28-20 11:19AM	Blueprint Medicines Tumbles 20.8% on Phase 3 Study Failure Motley Fool +16.12%
07:00AM	Deciphera Pharmaceuticals, Inc. to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 5, 2020 Business Wire
Apr-23-20 09:06AM	Is Deciphera Pharmaceuticals (DCPH) Stock a Solid Choice Right Now? Zacks
Mar-28-20 09:10PM	Hedge Funds Have Never Been This Bullish On Deciphera Pharmaceuticals, Inc. (DCPH) Insider Monkey
Mar-09-20 05:15PM	Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q4 Loss, Misses Revenue Estimates Zacks -9.99%
04:01PM	Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2019 Financial Results Business Wire
02:30PM	Deciphera Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Mar-02-20 07:00AM	Deciphera Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call and Webcast on March 9, 2020 Business Wire +7.10%
Feb-20-20 07:00AM	Deciphera Pharmaceuticals, Inc. to Present at the 9th Annual SVB Leerink Global Healthcare Conference Business Wire
Feb-19-20 04:01PM	Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock Business Wire
Feb-13-20 10:12PM	Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock Business Wire -15.78%
01:36PM	Revamped postal center in Waltham will sell for $320M American City Business Journals
10:31AM	Deciphera's NDA for GIST Drug Gets Priority Review From FDA Zacks
08:05AM	The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO Benzinga
Feb-12-20 04:14PM	Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
04:01PM	Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance of New Drug Application and Priority Review for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors Business Wire
Jan-13-20 09:00AM	Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2020 Milestones Business Wire
Jan-11-20 06:09PM	How Did Deciphera Pharmaceuticals, Inc. (DCPH) Compare Against Top Hedge Fund Stocks in 2019? Insider Monkey
Jan-06-20 07:00AM	Deciphera Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-02-20 06:40AM	Does Market Volatility Impact Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Share Price? Simply Wall St. -7.05%
Dec-17-19 07:56AM	The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO Benzinga +9.39%
Dec-16-19 07:00AM	Deciphera Pharmaceuticals Announces Submission of New Drug Application to U.S. FDA for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors Business Wire
Dec-05-19 03:47PM	Hedge Funds Have Never Been This Bullish On Deciphera Pharmaceuticals, Inc. (DCPH) Insider Monkey
Dec-04-19 04:05PM	Deciphera Pharmaceuticals Announces Appointment of Ron Squarer to its Board of Directors Business Wire
Nov-26-19 07:00AM	Deciphera Pharmaceuticals Expands its Board of Directors with Appointment of Frank S. Friedman TEST Business Wire Releases
07:00AM	Deciphera Pharmaceuticals Expands its Board of Directors with Appointment of Frank S. Friedman Business Wire
Nov-22-19 08:00PM	Callon, Fitbit, Genco Shipping and Other 13D Filings Barrons.com
Nov-13-19 04:30PM	Deciphera Pharmaceuticals, Inc. to Present Data from DCC-3014 and Ripretinib Programs at the Connective Tissue Oncology Society (CTOS) 2019 Annual Meeting Business Wire
07:00AM	Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences Business Wire
Nov-04-19 05:15PM	Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Misses Revenue Estimates Zacks

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase 1b/2 clinical trial to treat metastatic solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, it is developing DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. The company serves in the United States and Europe. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Taylor Michael Douglas	Director	Mar 01	Option Exercise	1.89	8,000	15,120	8,000	Mar 03 04:00 PM
Taylor Michael Douglas	Director	Mar 01	Sale	44.04	8,000	352,307	0	Mar 03 04:00 PM
Sherman Matthew L	EVP & Chief Medical Officer	Feb 16	Sale	48.87	132	6,451	37,286	Feb 18 07:00 PM
Flynn Daniel Lee	Chief Scientific Officer	Feb 16	Sale	48.87	508	24,826	6,532	Feb 18 07:00 PM
Kelly Thomas Patrick	Chief Financial Officer	Feb 16	Sale	48.87	524	25,608	6,516	Feb 18 07:00 PM
Taylor Michael Douglas	Director	Feb 01	Option Exercise	1.89	8,000	15,120	8,000	Feb 03 04:00 PM
Taylor Michael Douglas	Director	Feb 01	Sale	45.23	8,000	361,872	0	Feb 03 04:00 PM
Hoerter Steven L.	President and CEO	Jan 21	Option Exercise	25.40	1,078	27,381	43,845	Jan 25 05:00 PM
Bristol James Arthur	Director	Jan 15	Option Exercise	3.95	7,000	27,650	7,000	Jan 20 04:00 PM
Bristol James Arthur	Director	Jan 15	Sale	50.29	7,000	352,039	0	Jan 20 04:00 PM
Taylor Michael Douglas	Director	Jan 04	Option Exercise	1.89	19,000	35,910	19,000	Jan 06 04:10 PM
Taylor Michael Douglas	Director	Jan 04	Sale	56.45	19,000	1,072,497	0	Jan 06 04:10 PM
Sherman Matthew L	EVP & Chief Medical Officer	Dec 09	Option Exercise	34.43	207	7,127	37,418	Dec 11 04:10 PM
Taylor Michael Douglas	Director	Dec 01	Option Exercise	1.89	19,000	35,910	19,000	Dec 03 04:15 PM
Taylor Michael Douglas	Director	Dec 01	Sale	60.90	19,000	1,157,142	0	Dec 03 04:15 PM
Sherman Matthew L	EVP & Chief Medical Officer	Nov 16	Option Exercise	34.43	2,697	92,858	37,211	Nov 18 07:31 PM
Taylor Michael Douglas	Director	Nov 04	Option Exercise	1.89	15,000	28,350	15,000	Nov 06 04:00 PM
Taylor Michael Douglas	Director	Nov 04	Sale	64.80	15,000	971,987	0	Nov 06 04:00 PM
Taylor Michael Douglas	Director	Nov 02	Option Exercise	1.89	23,315	44,065	23,315	Nov 04 04:10 PM
Taylor Michael Douglas	Director	Nov 02	Sale	57.64	23,315	1,343,926	0	Nov 04 04:10 PM
Bristol James Arthur	Director	Oct 09	Option Exercise	1.89	23,541	44,492	23,541	Oct 13 04:20 PM
Bristol James Arthur	Director	Oct 09	Sale	53.57	23,541	1,261,069	0	Oct 13 04:20 PM
Taylor Michael Douglas	Director	Oct 01	Option Exercise	1.89	125,000	236,250	125,000	Oct 05 04:00 PM
Taylor Michael Douglas	Director	Oct 01	Sale	51.60	125,000	6,450,484	0	Oct 05 04:00 PM
Kelly Thomas Patrick	Chief Financial Officer	Sep 14	Option Exercise	1.89	3,000	5,670	10,040	Sep 16 04:00 PM
Kelly Thomas Patrick	Chief Financial Officer	Sep 14	Sale	50.01	3,000	150,036	7,040	Sep 16 04:00 PM
Kelly Thomas Patrick	Chief Financial Officer	Sep 10	Option Exercise	1.89	3,000	5,670	10,040	Sep 10 08:29 PM
Kelly Thomas Patrick	Chief Financial Officer	Sep 10	Sale	47.71	3,000	143,126	7,040	Sep 10 08:29 PM
Kelly Thomas Patrick	Chief Financial Officer	Sep 08	Option Exercise	1.89	6,000	11,340	13,040	Sep 10 08:29 PM
Kelly Thomas Patrick	Chief Financial Officer	Sep 08	Sale	45.49	6,000	272,929	7,040	Sep 10 08:29 PM
Hoerter Steven L.	President and CEO	Aug 20	Option Exercise	25.40	187	4,750	42,767	Aug 24 04:00 PM
Flynn Daniel Lee	Chief Scientific Officer	Aug 10	Option Exercise	1.89	9,029	17,065	237,475	Aug 12 04:00 PM
Flynn Daniel Lee	Chief Scientific Officer	Jul 22	Option Exercise	1.89	130,000	245,700	228,446	Jul 24 04:00 PM
Hoerter Steven L.	President and CEO	Jul 20	Option Exercise	25.40	188	4,775	42,580	Jul 22 04:00 PM
Bristol James Arthur	Director	Jul 09	Option Exercise	1.89	23,541	44,492	23,541	Jul 13 04:11 PM
Bristol James Arthur	Director	Jul 09	Sale	54.99	23,541	1,294,634	0	Jul 13 04:11 PM
Taylor Michael Douglas	Director	Jul 06	Option Exercise	1.89	27,544	52,058	27,544	Jul 06 06:16 PM
Taylor Michael Douglas	Director	Jul 06	Sale	55.22	27,544	1,520,873	0	Jul 06 06:16 PM
Taylor Michael Douglas	Director	Jul 02	Option Exercise	1.89	48,245	91,183	48,245	Jul 06 06:16 PM
Taylor Michael Douglas	Director	Jul 02	Sale	56.69	48,245	2,734,965	0	Jul 06 06:16 PM
Taylor Michael Douglas	Director	Jul 01	Option Exercise	1.89	49,211	93,009	49,211	Jul 06 06:16 PM
Taylor Michael Douglas	Director	Jul 01	Sale	58.87	49,211	2,896,889	0	Jul 06 06:16 PM
Hoerter Steven L.	President and CEO	Jun 18	Option Exercise	25.40	187	4,750	42,392	Jun 19 04:00 PM
Allen Patricia L	Director	Jun 05	Option Exercise	25.73	5,635	144,989	5,635	Jun 05 04:05 PM
Allen Patricia L	Director	Jun 05	Sale	55.90	5,635	314,999	0	Jun 05 04:05 PM
Allen Patricia L	Director	Jun 03	Option Exercise	25.73	6,365	163,771	6,365	Jun 05 04:05 PM
Allen Patricia L	Director	Jun 03	Sale	59.14	6,365	376,450	0	Jun 05 04:05 PM
Hoerter Steven L.	President and CEO	May 28	Option Exercise	25.40	188	4,775	42,205	Jun 01 04:05 PM
Kelly Thomas Patrick	Chief Financial Officer	May 11	Option Exercise	1.89	12,000	22,680	19,040	May 13 04:05 PM
Kelly Thomas Patrick	Chief Financial Officer	May 11	Sale	55.19	12,000	662,240	7,040	May 13 04:05 PM
Taylor Michael Douglas	Director	Apr 28	Option Exercise	1.89	25,000	47,250	25,000	Apr 30 04:05 PM
Taylor Michael Douglas	Director	Apr 28	Sale	56.90	25,000	1,422,490	0	Apr 30 04:05 PM
Hoerter Steven L.	President and CEO	Apr 21	Option Exercise	25.40	187	4,750	42,017	Apr 23 04:10 PM
Taylor Michael Douglas	Director	Apr 17	Option Exercise	1.89	23,892	45,156	23,892	Apr 21 04:05 PM
Taylor Michael Douglas	Director	Apr 17	Sale	46.67	23,892	1,115,150	0	Apr 21 04:05 PM
Taylor Michael Douglas	Director	Apr 14	Option Exercise	1.89	1,108	2,094	1,108	Apr 16 04:05 PM
Taylor Michael Douglas	Director	Apr 14	Sale	46.71	1,108	51,753	0	Apr 16 04:05 PM
Bristol James Arthur	Director	Apr 09	Option Exercise	1.89	23,542	44,494	23,542	Apr 13 07:47 PM
Bristol James Arthur	Director	Apr 09	Sale	43.83	23,542	1,031,840	0	Apr 13 07:47 PM
Taylor Michael Douglas	Director	Apr 01	Option Exercise	1.89	75,000	141,750	75,000	Apr 03 04:10 PM
Taylor Michael Douglas	Director	Apr 01	Sale	37.57	75,000	2,817,558	0	Apr 03 04:10 PM
Hoerter Steven L.	President and CEO	Mar 18	Option Exercise	25.40	2,250	57,150	54,250	Mar 20 05:49 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience